{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Prochymal",
            "NStudiesAvail": 430108,
            "NStudiesFound": 20,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 20,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT00294112"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL\u2122 IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "OSIRIS-601-602"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT00136903"
                        ],
                        "NCTIdAlias": [
                              "NCT00476762"
                        ],
                        "OfficialTitle": [
                              "A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal\u00ae (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "260-261"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "6 Months"
                        ],
                        "NCTId": [
                              "NCT00366145"
                        ],
                        "NCTIdAlias": [
                              "NCT00476840"
                        ],
                        "OfficialTitle": [
                              "A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal\u00ae (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "280"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [
                              "35 Years"
                        ],
                        "MinimumAge": [
                              "12 Years"
                        ],
                        "NCTId": [
                              "NCT00690066"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL\u00ae (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "901"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04543994"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase IB/IIA Study of Remestemcel-L, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product, for the Treatment of Medically Refractory Ulcerative Colitis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "The Cleveland Clinic"
                        ],
                        "OrgStudyId": [
                              "20-1005"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 6,
                        "MaximumAge": [
                              "75 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04548583"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase IB/IIA Study of Remestemcel-L, an Ex-vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product for the Treatment of Medically Refractory Crohn's Colitis"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "The Cleveland Clinic"
                        ],
                        "OrgStudyId": [
                              "20-845"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 7,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "6 Months"
                        ],
                        "NCTId": [
                              "NCT00284986"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase II Open Label Study to Evaluate the Safety and Efficacy of Prochymal\u00ae (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Salvage of Treatment-Refractory Acute GVHD Patients"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "Osiris 270-271"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 8,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "40 Years"
                        ],
                        "NCTId": [
                              "NCT00683722"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL\u2122 (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "801"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 9,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT00543374"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL\u00ae (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "CRD 610"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 10,
                        "MaximumAge": [
                              "17 Years"
                        ],
                        "MinimumAge": [
                              "2 Months"
                        ],
                        "NCTId": [
                              "NCT02336230"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "MSB-GVHD001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [
                              "Blood and lymphatic system disorders",
                              "Blood and lymphatic system disorders",
                              "Cardiac disorders",
                              "Cardiac disorders",
                              "Cardiac disorders",
                              "Endocrine disorders",
                              "Endocrine disorders",
                              "Gastrointestinal disorders",
                              "Gastrointestinal disorders",
                              "Gastrointestinal disorders",
                              "Gastrointestinal disorders",
                              "Gastrointestinal disorders",
                              "Gastrointestinal disorders",
                              "Gastrointestinal disorders",
                              "Gastrointestinal disorders",
                              "Gastrointestinal disorders",
                              "General disorders",
                              "General disorders",
                              "General disorders",
                              "Hepatobiliary disorders",
                              "Immune system disorders",
                              "Immune system disorders",
                              "Immune system disorders",
                              "Infections and infestations",
                              "Infections and infestations",
                              "Infections and infestations",
                              "Infections and infestations",
                              "Infections and infestations",
                              "Infections and infestations",
                              "Infections and infestations",
                              "Infections and infestations",
                              "Injury, poisoning and procedural complications",
                              "Investigations",
                              "Investigations",
                              "Investigations",
                              "Investigations",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Metabolism and nutrition disorders",
                              "Musculoskeletal and connective tissue disorders",
                              "Musculoskeletal and connective tissue disorders",
                              "Musculoskeletal and connective tissue disorders",
                              "Nervous system disorders",
                              "Nervous system disorders",
                              "Psychiatric disorders",
                              "Psychiatric disorders",
                              "Psychiatric disorders",
                              "Renal and urinary disorders",
                              "Renal and urinary disorders",
                              "Renal and urinary disorders",
                              "Respiratory, thoracic and mediastinal disorders",
                              "Respiratory, thoracic and mediastinal disorders",
                              "Respiratory, thoracic and mediastinal disorders",
                              "Skin and subcutaneous tissue disorders",
                              "Skin and subcutaneous tissue disorders",
                              "Skin and subcutaneous tissue disorders",
                              "Skin and subcutaneous tissue disorders",
                              "Vascular disorders",
                              "Vascular disorders"
                        ],
                        "OtherEventSourceVocabulary": [
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0",
                              "MedDRA 20.0"
                        ]
                  },
                  {
                        "Rank": 11,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT00482092"
                        ],
                        "NCTIdAlias": [
                              "NCT00609232"
                        ],
                        "OfficialTitle": [
                              "A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL\u00ae (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "CRD 603"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 12,
                        "MaximumAge": [
                              "85 Years"
                        ],
                        "MinimumAge": [
                              "21 Years"
                        ],
                        "NCTId": [
                              "NCT00877903"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL\u00ae (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "403"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 13,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT00826046"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Expanded Access of Prochymal\u00ae (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "276"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 14,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04366830"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Intermediate-size Expanded Access of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome Due to COVID-19 Infection"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "MSB-MSC-ARDS001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 15,
                        "MaximumAge": [
                              "17 Years"
                        ],
                        "MinimumAge": [
                              "2 Months"
                        ],
                        "NCTId": [
                              "NCT00759018"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "275"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 16,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04371393"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome"
                        ],
                        "OrgClass": [
                              "OTHER"
                        ],
                        "OrgFullName": [
                              "Icahn School of Medicine at Mount Sinai"
                        ],
                        "OrgStudyId": [
                              "GCO 08-1078-0014"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 17,
                        "MaximumAge": [
                              "17 Years"
                        ],
                        "MinimumAge": [
                              "2 Months"
                        ],
                        "NCTId": [
                              "NCT04456439"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "MSB-MSC-MISC001"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 18,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01233960"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL\u00ae (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "CRD 611"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 19,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT01510431"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "An Open-label Compassionate Treatment Protocol to Evaluate the Safety and Treatment Outcomes of PROCHYMAL\u00ae (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "CRD 620"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 20,
                        "MaximumAge": [
                              "70 Years"
                        ],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT00562497"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal\u00ae Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Mesoblast, Ltd."
                        ],
                        "OrgStudyId": [
                              "265"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}